Quantifying the Public Health Impact of Lyme Disease in Minnesota: A Simulation Analysis of Reported and Unreported Cases
Kathleen E. Angell, M. Jana Broadhurst, Jianghu J. Dong, Tzeyu L. Michaud, Abraham Degarege, Roberto Cortinas, David M. Brett-Major
TL;DR
This study estimates the hidden health and cost burden of Lyme disease in Minnesota and shows how public health interventions during high-risk years could significantly reduce cases and costs.
Contribution
The paper introduces a simulation-based approach to quantify the impact of underreported Lyme disease and evaluates the potential benefits of targeted public health interventions.
Findings
An average of 8436 Lyme disease cases occur annually in Minnesota, with 6074 cases unreported.
High-incidence years result in over 3700 more cases and incremental costs exceeding $3 million compared to low-incidence years.
Public health education before high-incidence years could reduce cases by 390-787 annually, saving up to $1.9 million in societal costs.
Abstract
Background: Lyme disease, the most common vector-borne disease in Minnesota, is estimated to be underreported by a factor of 10. Delayed diagnosis and misdiagnosis may lead to health complications and increased personal and societal costs. Environmental factors can help to predict high disease years, allowing for early intervention to decrease disease burden. Objective: To estimate the health and cost burdens of Lyme disease and the extent to which they could be diminished by public health intervention when high-incidence Lyme disease years are forecasted. Methods: We used 5 two-dimensional Monte Carlo simulations to estimate (1) average annual expected burden of Lyme disease, (2 and 3) average burden in low- and high-incidence years, and (4 and 5) the expected burden saved with public health educational interventions preceding high-incidence years. We employed cases reported to the…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Case counts | |||||
| Estimated annual cases | Average cases with underreporting multiplication factor | 10× | 1-5 | Fixed | Cook et al, 2020 |
| Reported cases | Average cases in 7-county metro by year ± SD | n = 883.6 | 1-5 | Variability | Annual incidence (2014-2018) provided by MDH |
| Clinician-diagnosed cases | Reported cases × 2.8 underreporting multiplier | 2.8× | 1-5 | Fixed | Schiffman et al, 2018 |
| Unreported cases | Estimated total clinician diagnosed cases minus reported cases | NA | 1-5 | NA | NA |
| Unidentified cases | Estimated annual cases minus clinician diagnosed and treated cases | NA | 1-5 | NA | NA |
| Protective clothing | Proportion of cases prevented with use of protective clothing when spending time outdoors | Probability = 0.40 | 4 | Uncertainty | Vasquez et al, 2008 |
| Tick repellent | Proportion of cases prevented with use of tick repellent when spending time outdoors | Probability = 0.20 | 5 | Uncertainty | Vasquez et al, 2008 |
| Behavior uptake | Proportion of the public expected to uptake personal protective behaviors with educational interventions | Probability = 0.19 | 4-5 | Uncertainty | Daltroy et al, 2007 |
| Outcomes | |||||
| Delayed treatment | Proportion of patients with >30 days between symptom onset and treatment | Probability = 0.31 | 1-5 | Uncertainty | Hirsch et al, 2020 |
| PTLDS | Proportion of patients with persistent symptoms for >6 mo | ||||
| Given on-time treatment | Probability = 0.073 | 1-5 | Uncertainty | Hirsch et al, 2020 | |
| Given delayed treatment | Probability = 0.14 | 1-5 | Uncertainty | Hirsch et al, 2020 | |
| Cost to patients | Estimated medical, nonmedical, and cost of productivity losses from patient perspective | ||||
| Given PTLDS | $5050/person | 1-5 | Variability | Hook et al, 2022, | |
| Given no PTLDS, and for unidentified cases | $1252/person | 1-5 | Variability | Hook et al, 2022 | |
| Societal medical costs | Total estimated medical costs from community perspective | $1333/person | 1-5 | Variability | Hook et al, 2022 |
| Disability-adjusted life-years (DALYs) lost | Average DALYs lost per case of Lyme disease | 1.661 | 1-5 | Fixed | van den Wijngaard et al, 2015 |
| Neuroborreliosis | Proportion of patients experiencing this disorder | Probability = 0.08 | 1-5 | Uncertainty | Berglund et al, 2009 |
| Residual neurologic | Proportion of neuroborreliosis patients reporting residual neurologic symptoms 5 y post treatment | Probability = 0.25 | 1-5 | Uncertainty | Berglund et al, 2009 |
| Lyme carditis | Proportion of patients suffering from this condition | Probability = 0.04-0.10; uniform distribution | 1-5 | Uncertainty | Krause et al, 2013 |
|
|
|
|
|
|---|---|---|---|
| Overall cases | 10 418 (6314-14 709) | 6714 (4723-8796) | 3704 (1590-5913) |
| Clinician-identified cases | |||
| Reported cases | 1091 (661-1540) | 703 (495-921) | 388 (167-619) |
| Unreported cases | 1826 (1107-2578) | 1177 (828-1542) | 649 (29-1036) |
| Delayed treatment | 901 (546-1272) | 580 (408-760) | 320 (137-511) |
| PTLDS | |||
| With delayed treatment | 127 (77-179) | 82 (58-107) | 45 (19-72) |
| Without delayed treatment | 146 (88-206) | 94 (66-123) | 52 (22-83) |
| Cost-identified patients | |||
| With PTLDS | $1489 (228-5197) | $936 (171-3108) | $553 (58-2089) |
| Without PTLDS | $4009 (44-31 061) | $2446 (33-18 575) | $1563 (11-12 486) |
| Societal medical costs | $4844 (14-43 073) | $2928 (11-25 758) | $1917 (4-17 314) |
| DALYs lost | 4545 (2936-6841) | 3123 (2197-4091) | 1722 (740-2750) |
| Neuroborreliosis | 257 (155-362) | 165 (116-217) | 91 (39-146) |
| Residual neurologic symptoms | 63 (38-89) | 41 (29-53) | 23 (10-36) |
| Unidentified cases | |||
| All | 7501 (4546-10 591) | 4834 (3401-6333) | 2667 (1145-4257) |
| Lyme carditis | 523 (317-738) | 337 (237-441) | 186 (80-297) |
| Neuroborreliosis | 660 (400-931) | 425 (299-557) | 234 (101-374) |
| Residual neurologic symptoms | 163 (99-230) | 105 (74-137) | 58 (25-92) |
| DALYs lost | 12 459 (7550-17 591) | 8030 (5648-10 520) | 4429 (1902-7071) |
| Cost to unidentified patients | $8925 (5409-12 601) | $5752 (4046-7536) | $3173 (1362-5066) |
| Societal medical costs | $12 458 (38-110 758) | $7529 (29-66 234) | $4929 (10-44 524) |
|
|
|
|
|
|
|---|---|---|---|---|
| Overall cases | 9631 (5837-13 598) | 787 (477-1111) | 10 031 (6077-14 158) | 390 (236-551) |
| Clinician-identified cases | ||||
| Reported cases | 1009 (611-1424) | 82 (50-116) | 1050 (636-14 158) | 41 (25-58) |
| Unreported cases | 1688 (1023-2383) | 138 (84-195) | 1758 (1065-2482) | 68 (41-97) |
| Delayed treatment | 832 (504-1175) | 69 (42-97) | 866 (525-1223) | 35 (21-49) |
| PTLDS | ||||
| With delayed treatment | 117 (71-165) | 10 (6-14) | 122 (74-172) | 5 (3-7) |
| Without delayed treatment | 135 (82-190) | 11 (7-16) | 140 (85-198) | 6 (3-8) |
| Cost to identified patients | ||||
| With PTLDS | 211-$4793) | 18-$403) | 219-$4988) | 9-$209) |
| Without PTLDS | 40-$28 721) | 3-$2340) | 42-$29 906) | 1-$1156) |
| Societal medical costs | 14-$39 818) | 1-$3254) | 14-$41 459) | -8-$1615) |
| DALYs lost | 4479 (2714-6324) | 366 (222-517) | 4664 (2826-6585) | 182 (110-256) |
| Neuroborreliosis | 237 (144-334) | 20 (12-28) | 247 (149-348) | 10 (6-14) |
| Residual neurologic symptoms | 58 (35-82) | 5 (3-7) | 61 (37-86) | 3 (2-4) |
| Unidentified cases | ||||
| All | 6934 (4202-9790) | 567 (343-800) | 7220 (4375-10 194) | 281 (170-397) |
| Lyme carditis | 483 (293-682) | 40 (24-56) | 503 (305-710) | 20 (12-28) |
| Neuroborreliosis | 609 (369-860) | 51 (31-71) | 634 (384-895) | 26 (16-36) |
| Residual neurologic symptoms | 150 (91-212) | 13 (8-18) | 156 (95-220) | 7 (4-10) |
| DALYs lost | 11 518 (6980-16 262) | 941 (570-1329) | 11 992 (7268-16 932) | 467 (283-659) |
| Cost to unidentified patients | $8096 (4906-11 430) | $829 (503-1171) | $8386 (5082-11 841) | $538 (326-760) |
| Societal medical costs | 35-$102 390) | 3-$8368) | 37-$106 608) | -1 to $4152) |
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsVector-borne infectious diseases · Mosquito-borne diseases and control · Parasites and Host Interactions
INTRODUCTION
Lyme disease is the most common vector-borne disease reported in Minnesota and the United States, with over 2600 and 63 000 cases reported in 2022, respectively.1,2 The US Centers for Disease Control and Prevention (CDC) estimates that case counts are 10 times higher than reported, which is supported by several studies.3–6 In Minnesota, a study examining physician reporting found that Lyme disease cases meeting the case definition were underreported by a factor of 2.8.7 It is unknown to what extent Lyme disease cases in Minnesota are underdiagnosed or misdiagnosed vs unreported.
Lyme disease is characterized by 3 clinical stages: early localized, early disseminated, and late disseminated. Timely diagnosis and treatment lead to most people recovering within a few weeks.8,9 Delays in diagnosis may lead to complications including meningitis, Bell’s palsy, carditis, arthritis, more intensive treatment regimens, and increased costs.8–10 Among those treated, 10% will develop posttreatment Lyme disease syndrome (PTLDS), characterized by persistent symptoms lasting 6 months after treatment.9,11 Due to nonspecific symptoms in the early localized stage, misdiagnosis (>50% of cases) and delayed treatment (>30%) remain common.11,12 The burden of these outcomes on a population level is largely unknown.
Tick abundance and environmental factors are associated with high seasons of human risk for Lyme disease in the same year and up to 2 years in advance.13–15 Predictive systems, when used for early warning of high-incidence years, present an opportunity for cost-effective public health intervention through tick bite prevention education. While estimates for the efficacy of prevention measures in reducing Lyme disease exist, their impact on reducing population-level disease burden remains underexplored.16–19
Lyme disease incidence from the Minnesota Department of Health (MDH), along with estimated rates for underreporting, adverse outcomes, and efficacy of preventive measures, each can inform models assessing population effects of disease and potential benefits of early warning. The objective of this study was to estimate population health burden, economic cost, and disability-adjusted life-years (DALYs) lost from Lyme disease and the extent to which these outcomes could be diminished by public health education implemented in years when predictive models forecast high Lyme disease incidence.
METHODS
Model Description
We used 2-dimensional Monte Carlo simulations to estimate the health and economic burden of Lyme disease in the 7-county Twin Cities metropolitan area of Minnesota, which has a population of over 3 million.20 We used the number of Lyme disease cases reported to MDH between 2014 and 2023 and factors affecting the variability of these inputs to obtain estimates of burden. The 2-dimensional approach allows us to account for both variability (naturally occurring heterogeneity) and uncertainty (imprecision around a true value) of factors included in the simulations.
Model Inputs and Outcomes
Factors affecting simulated Lyme disease case counts and outcomes, input effects used, and their definition are presented in Table 1. We calculated the mean and SD for the number of cases reported to MDH between 2014 and 2023 and then multiplied this number by 10, the factor by which Lyme disease is estimated to be underreported nationally, to obtain estimated annual cases for the 7-county metropolitan area.6 We multiplied the number of reported cases to MDH by 2.8 to estimate the number of cases that were diagnosed and treated, regardless of their reporting status.7 We subtracted the number of clinician-diagnosed cases from the overall estimated cases to determine the number of unidentified cases, either through missed diagnosis, failure to seek care and treatment, or other means.
The simulation structure was divided into two parts, one estimating burden for cases that were diagnosed and treated (clinician-identified cases) and the other for unidentified cases. Outcomes estimated for unidentified cases included the number of people with Lyme carditis, neuroborreliosis, residual neurologic sequelae 5 years post treatment for those with a neuroborreliosis diagnosis, DALYs lost, cost to patients (medical, nonmedical, and productivity losses), and societal medical costs (cost of all Lyme disease–related medical services). Outcomes estimated for identified cases were delayed treatment (>30 days from symptom onset to treatment), PTLDS (estimated separately based on timely or delayed treatment), cost to patients (estimated separately based on diagnosis of PTLDS), societal medical costs, DALYs lost, neuroborreliosis, and residual neurologic sequelae 5 years after treatment for those with neuroborreliosis. A normal distribution was used for most outcomes, except for Lyme carditis, which followed a uniform distribution, and patient and societal costs, which were modeled using a log-normal distribution to account for right-skewed data.
Simulation 1 estimated average disease outcomes across all years. Simulation 2 estimated average disease outcomes across only high-incidence Lyme disease years. Simulation 3 estimated average disease outcomes across only low-incidence Lyme disease years. Simulation 4 and 5 estimated average disease outcomes across high-incidence years if educational programs targeting use of protective clothing and tick repellent had been implemented. Based on prior evidence, we assumed that 19% of individuals not practicing preventive behaviors would adopt protective measures following educational interventions16 and that protective clothing (simulation 4) and tick repellent (simulation 5) would yield 40% and 20% efficacy in preventing Lyme disease, respectively.18
Data Analysis
All estimation models used the mc2d package in R software, running 1000 iterations each for variability and uncertainty dimensions. R code can be found in the Supplementary File. Five sets of burden outcomes were modeled. Simulation 1 estimated the burden of Lyme disease cases reported to MDH, adjusted for underreporting estimations, using data from 2014 to 2023. Simulation 2 provided outcome estimations for years with high Lyme disease incidence, defined as years with case counts above the 50th percentile (2016-2017 and 2022-2023). Simulation 3 provided outcome estimations for years with low Lyme disease incidence, defined as years with case counts at or below the 50th percentile (2014-2015, 2018-2019, and 2021). Simulations 4 and 5 estimated high Lyme disease incidence years adjusting for cases saved from theoretical education programs targeting the use of protective clothing (simulation 4) and tick repellent (simulation 5) when spending time outdoors. Figure 1 shows a depiction of the simulation structure which flows from estimated annual cases of Lyme disease to estimated burden outcomes. Means and 95% confidence intervals (CI) were provided for the case categories and burden outcomes (Figure 1). Burden estimates from simulations 4 and 5 were subtracted from those in simulation 2 to provide means and 95% CI to estimate burden saved when educational interventions are implemented in high-incidence years.
Monte Carlo Simulation 1 Output and Structure (Estimated Average Annual Cases and Outcomes: 2014-2023)Abbreviations: DALY, disability-adjusted life-year; PTLDS, posttreatment Lyme disease syndrome.
Assessing Uncertainty
A sensitivity analysis on overall cost to patients among clinician-identified cases was performed to assess the lability of the modeling from changes in individual input parameters. The analysis was performed on the simulation 1 model for average burden across all years. Input parameters for reported cases, delayed treatment, and PTLDS were independently varied by 1 SD above and below their estimated values (Table 1), then entered into the model while holding all other parameters constant. Estimated cost to patients varied by 50% above and below the estimated value due to its distribution.
RESULTS
Simulation 1 estimated 8436 (95% CI, 7941-8953) annual cases in the Minnesota Twin-Cities metropolitan area (Figure 1). Over 2300 estimated cases were diagnosed and treated by a physician with over 6000 unidentified cases. Among clinician-identified cases, we estimated over 700 cases with delay to treatment, 200 cases of PTLDS, 200 cases of neuroborreliosis, 3900 DALYs lost, more than 3.1 million in societal costs. Among unidentified cases, we estimated over 400 cases of Lyme carditis; 500 cases of neuroborreliosis, including 100 with residual neurologic sequelae; 10 000 DALYs lost; 7.9 million in societal costs annually.
Case count estimates from simulations 2 and 3 and estimated differences are shown in Table 2. On average, high-incidence Lyme disease years (simulation 2) yielded 3704 (1590-5913) more cases than low-incidence years (simulation 3). Among clinician-identified cases, high-incidence years account for 320 more cases of delayed treatment, 97 of PTLDS, 1722 DALYs lost, 91 of neuroborreliosis, over 1.9 million in societal costs. Among the 2667 additional unidentified cases, the simulation estimated 186 more cases of Lyme carditis; 234 of neuroborreliosis, 58 with residual neurologic symptoms; 4429 DALYs lost; 4 million in societal costs.
Simulations 4 and 5 estimated 9% and 4% of cases, respectively, to be prevented in high-incidence years given educational interventions targeting protective clothing and tick repellent use. Outcomes for simulations 4 and 5 and differences in outcomes can be found in Table 3. Educational interventions targeting the use of protective clothing would prevent 787 (95% CI, 477-1111) cases annually in high-incidence years. Additionally, among cases identified by a clinician, 69 cases of delayed treatment, 366 DALYs lost, 21 cases of PTLDS, over 300 000 in societal costs would be prevented. Among the 567 unidentified cases that could be prevented, 40 cases of Lyme carditis, 51 cases of neuroborreliosis, 941 DALYs lost, over 900 000 in societal costs could also be prevented. Interventions targeting the use of tick repellent would prevent 390 (95% CI, 236-551) cases per year including 35 cases of delayed treatment, 11 cases of PTLDS, 182 DALYs lost, 10 cases of neuroborreliosis, over 180 000 in societal costs among cases identified by a clinician. Among the 281 preventable unidentified cases 20 cases of Lyme carditis, 26 cases of neuroborreliosis, 467 DALYs lost, 400 000 in societal costs could be prevented.
In sensitivity analysis, preventable patient costs remained apparent even with large changes in input parameters. Figure 2 summarizes the impact of changes to parameters on overall cost to patients for the simulation 1 model. Estimates for cost have the highest impact on variation in the outcome, changing the simulated estimate by up to 10 000. Varying the estimates for reported cases and PTLDS changes the estimate by about 130 000, respectively.
Sensitivity of Patient Costs to Changes in Individual ParametersAbbreviation: PTLDS, posttreatment Lyme disease syndrome.Parameter variation by 1 SD above and below the mean, except for estimated cost to patients which varied by 50%.
DISCUSSION
This simulation, the first of its kind in Minnesota, presents substantial health and cost burden attributable to Lyme disease. In addition to high cost and DALYs lost, these outcomes depict the hidden burden of infected individuals who remain unidentified, reflecting the impact of underreporting and underdiagnosis. Simulations 4 and 5 reflect the burden and cost savings that could be attained in high-incidence years when tick bite prevention education is implemented. Given the substantial differences in burden and cost between high- and low-incidence years, implementing strategies to mitigate incidence in the high-incidence years should be a priority.
Simulation 1 showed a significant population-level health burden, particularly given estimates for underreporting, which identified over 1400 clinician-diagnosed cases unreported and 6000 unidentified cases. These results were particularly staggering when we explored the downstream estimates, such as over 200 PTLDS cases, 69 499, making estimates for DALYs lost and the actual cost to society even more staggering.25 These estimates uncover the known (reported cases) and unknown (unreported and unidentified) impacts of Lyme disease in the population.
Heightened average case numbers and health burdens in high-incidence Lyme disease years presents an opportunity for public health intervention, particularly given that high-incidence years can be predicted through environmental factors as far as 2 years in advance and through tick abundance measures in the same year.19 Simulations 4 and 5 show an estimated 9% (787) and 4% (390) of cases can be prevented annually in high-incidence years through tick bite prevention interventions. While these numbers may seem small given the overall burden of disease, they represent real savings in health outcomes, DALYs lost, and cost. Additionally, while this study estimates the impact of tick bite prevention measures individually, real-world educational interventions typically promote multiple preventive strategies. This could further enhance case reductions, potentially yielding a multiplicative effect when measures are combined.
We introduced an estimate to account for the proportion of people above the baseline expected to adopt preventive behavior after educational intervention. In the source used, 39% of individuals were already practicing preventive behavior and an additional 19% started the behavior after education.16 This estimate (19%) highlights the need for further research to optimize behavior change interventions for vector-borne disease prevention, with the goal of increasing the proportion of individuals who adopt protective behaviors. In this study, we simulated the burden saved from interventional programs in high-disease-incidence years as opposed to all years. Evidence exists suggesting chronic message fatigue, where populations are exposed to similar risk communication messaging over a prolonged period, induces a state of resistance to health behaviors in the population.26 Implementing tick bite prevention interventions beyond normal messaging in high-incidence years allows for high impact while avoiding message fatigue.
The sensitivity analysis suggests the model to be robust when exploring overall cost to patients, the most downstream outcome in the model structure. Given the wide CI for the cost parameter input, it is unsurprising that changing this estimate has the largest effect on the simulated value. Variation in the delay to treatment estimate has the smallest effect on patient costs, probably due to relatively narrow confidence limits of the estimate. Findings from this analysis suggest that the overall impact of a parameter estimate is primarily influenced by two factors: its position within the model hierarchy and the breadth of its confidence interval. PTLDS does not have a particularly wide CI, but is the second most influential parameter, likely due to its position in the model structure and it’s downstream effects on cost.
Wide CIs in cost estimates reflect uncertainty in the data, which likely arises from the variability in patient experiences, ranging from early identification and treatment with lower costs to delayed diagnosis associated with more severe symptoms, complex treatment and higher costs to both patients and society. Patient cost estimates used considered insurance status of individuals; 70% of study participants had private insurance, likely deflating this cost estimate.10 Individuals without private insurance and uninsured individuals likely bear the highest burden of cost, presenting a barrier to access to care. While insurance status was not factored into our simulation estimates, those who are uninsured or underinsured are more likely to delay or not seek medical care at all, putting this group at enhanced risk for late-disseminated disease and more severe symptoms.27 Public health interventions should address this gap in health equity through education on early symptoms of Lyme disease for high-risk groups, as well as resources for testing and treatment among uninsured and underinsured groups.
The unidentified cases in the simulation structure presents potential error and misclassification bias. These cases may be unidentified due to missed diagnosis by a physician, failure to seek care, either due to access barriers or mild to asymptomatic presentation. Alternatively, perhaps the patient was correctly diagnosed and treated but not reported or documented appropriately. Although the CDC and others estimate a 10-fold underestimation of Lyme disease cases, it is possible this is more applicable to the endemic Northeast rather than the Midwest. Additionally, we estimated unreported but diagnosed and treated cases with a multiplication factor of 2.8, identified by a study that took place in an endemic county in Minnesota outside the metropolitan area. It is possible this estimate is not accurate for the 7-county metropolitan area. If the CDC underestimation factor is inflated, or the Minnesota underreporting factor is deflated, the numbers in the unidentified category would decrease. As the unidentified cases in this study are largely an unknown entity, we erred toward conservative estimates, including inputs for the general Lyme disease population for outcomes such as DALYs, cost, and neuroborreliosis. Incidence of Lyme carditis was estimated for the unidentified cases only as the condition is associated with chronically untreated Lyme disease, making the condition extremely rare among those diagnosed and treated.28 Given gaps in knowledge associated with the unidentified cases, it is unknown whether the range used to estimate carditis is an overestimation or an underestimation.
One strength of this study is its integration of estimates from a variety of sources to comprehensively assess the burden of Lyme disease in an understudied Lyme-endemic region of the country. While several studies can be found estimating the burden of specific Lyme disease outcomes in the United States, there is a paucity of those estimating burden on the population level with adjustments for underreporting rates.21–23,29,30 Additionally, the use of two-dimensional Monte Carlo simulation allowed us to account for both variability and uncertainty within the model structure. This method allowed us to simulate a variety of burden outcomes, nested within each other, allowing the error at one level to impact the outcome of others. One limitation is the societal cost simulated considers all medical costs regardless of the payer but does not account for indirect costs such as productivity losses. Another limitation of this study is the use of estimates from secondary sources, which may not always be generalizable to the population of the Minnesota 7-county Twin Cities metropolitan area. Although we expected estimates to vary to some degree geographically, the incorporation of error estimates helped to account for the variation expected in our population. Some studies have noted differences between the Midwest and Northeast in the environmental factors that impact tick abundance and risk of Lyme disease based on vector infection, emphasizing the importance that this work be conducted in different regions in order to gain a more accurate national perspective.31,32
CONCLUSIONS
Lyme disease presents significant public health burden with high individual and societal costs, particularly in high-incidence years. Underreporting, underdiagnosis, and misdiagnosis of Lyme disease lead to uncertainty regarding true burden, although our simulations showed that over 6000 cases are unaccounted annually in Minnesota alone. Given the ability to forecast high-incidence years, implementing tick bite prevention education in anticipation of these years is a logical and proactive public health strategy. Simulation results presented here show substantial economic savings that could outweigh the cost of implementation.
Supplementary Material
Online Supplementary MaterialR Code for Estimation Models
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Diseases that can be transmitted by ticks Minnesota Department of Health 3012024 https://www.health.state.mn.us/diseases/tickborne/diseases.html
- 2Lyme disease US Centers for Disease Control and Prevention https://www.cdc.gov/lyme/index.html
- 3Estimates for Lyme borreliosis infections based on models using sentinel canine and human seroprevalence data Infect Dis Model Cook M. J. Puri B. K. 2020587188810.1016/j.idm.2020.10.004https://doi.org/10.1016/j.idm.2020.10.00433210054 PMC 7644786 · doi ↗ · pubmed ↗
- 4Lyme disease testing by large commercial laboratories in the United States Clin Infect Dis Hinckley A. F. Connally N. P. Meek J. I.. 201459567668110.1093/cid/ciu 397https://doi.org/10.1093/cid/ciu 39724879782 PMC 4646413 · doi ↗ · pubmed ↗
- 5Incidence of clinician-diagnosed Lyme disease, United States, 2005-2010 Emerg Infect Dis Nelson C. A. Saha S. Kugeler K. J.. 20152191625163110.3201/eid 2109.150417 https://doi.org/10.3201/eid 2109.150417 PMC 455014726291194 · doi ↗ · pubmed ↗
- 6CDC estimates 300,000 US cases of Lyme disease annually JAMA Kuehn B. M. 201331011111010.1001/jama.2013.278331 https://doi.org/10.1001/jama.2013.27833124045727 · doi ↗ · pubmed ↗
- 7Underreporting of Lyme and other tick-borne diseases in residents of a high-incidence county, Minnesota, 2009 Zoonoses Public Health Schiffman E. K. Mc Laughlin C. Ray J. A. E.. 201865223023710.1111/zph.12291 https://doi.org/10.1111/zph.1229127390047 · doi ↗ · pubmed ↗
- 8Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease Clin Infect Dis Lantos P. M. Rumbaugh J. Bockenstedt L. K.. 20217211810.1093/cid/ciab 049https://doi.org/10.1093/cid/ciab 04933483734 · doi ↗ · pubmed ↗